NEFL and Alzheimer disease: Our findings of abnormal levels of GFAP in MCI‐LB and its association with Aβ deposition starting from the iRBD stage supports the hypothesis that GFAP is, indeed, an early AD biomarker that increases before p‐tau or NfL in the course of the disease within the DLB continuum.